Amphista Therapeutics Limited

Amphista Therapeutics Limited company information, Employees & Contact Information

Explore related pages

Amphista Therapeutics Limited email format Amphista Therapeutics Limited management contacts

Related company profiles:

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Company Details

Employees
65
Founded
-
Address
The Cori Building, Granta Park, Great Abington,, Cambridge,cambridgeshire Cb21 6gq,united Kingdom
Email
in****@****sta.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
amphista.com
Keywords
Targeted Protein Degradation, Biology, Chemistry, Drug Discovery, Development.
HQ
Cambridge, Cambridgeshire
Competitors
Artios, Bicycle Therapeutics, Apollo Therapeutics, bit.bio, Quell Therapeutics, Crescendo Biologics Limited, Alchemab Therapeutics Ltd, TRIMTECH Therapeutics Limited, Mestag Therapeutics, Maxion Therapeutics.
Looking for a particular Amphista Therapeutics Limited employee's phone or email?

Amphista Therapeutics Limited Questions

News

Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025 - The Manila Times

Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025 The Manila Times

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer - GlobeNewswire

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer GlobeNewswire

Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications - The Manila Times

Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications The Manila Times

Amphista Therapeutics describes new BRD9 degradation inducers - BioWorld MedTech

Amphista Therapeutics describes new BRD9 degradation inducers BioWorld MedTech

Amphista earns milestone via Merck alliance - Business Weekly

Amphista earns milestone via Merck alliance Business Weekly

Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics - PR Newswire

Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics PR Newswire

Protein Knockdowns May Obviate Genetic Knockouts - Genetic Engineering and Biotechnology News

Protein Knockdowns May Obviate Genetic Knockouts Genetic Engineering and Biotechnology News

Amphista demonstrates protein degraders’ ‘rapid’ efficacy against tumor, CNS targets in animals - Fierce Biotech

Amphista demonstrates protein degraders’ ‘rapid’ efficacy against tumor, CNS targets in animals Fierce Biotech

Amphista Lands Megadeals to Smash Cancer using Protein Degradation - Labiotech.eu

Amphista Lands Megadeals to Smash Cancer using Protein Degradation Labiotech.eu

BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform - BioSpace

BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform BioSpace

Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more - BioCentury

Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more BioCentury

Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development - The Manila Times

Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development The Manila Times

Amphista – a life sciences spin out from the University of Dundee - Universities Scotland

Amphista – a life sciences spin out from the University of Dundee Universities Scotland

Amphista nominates AMX-883 as development candidate - BioWorld MedTech

Amphista nominates AMX-883 as development candidate BioWorld MedTech

BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships - Fierce Biotech

BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnerships Fierce Biotech

Amphista Therapeutics Is Silencing Disease Proteins to Treat Cancer - Labiotech.eu

Amphista Therapeutics Is Silencing Disease Proteins to Treat Cancer Labiotech.eu

New TEAD1 degradation inducers disclosed in Amphista patent - BioWorld MedTech

New TEAD1 degradation inducers disclosed in Amphista patent BioWorld MedTech

Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia - The Manila Times

Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia The Manila Times

Beverley Carr appointed Chief Business Officer for Amphista Therapeutics - Pharmafile

Beverley Carr appointed Chief Business Officer for Amphista Therapeutics Pharmafile

Louise Modis joins Amphista Therapeutics senior team as CSO while Ian Churcher becomes CTO - Cambridge Independent

Louise Modis joins Amphista Therapeutics senior team as CSO while Ian Churcher becomes CTO Cambridge Independent

Amphista Therapeutics targets success from new Granta Park base - Cambridge Independent

Amphista Therapeutics targets success from new Granta Park base Cambridge Independent

Amphista Therapeutics earns Series B investment from Dementia Discovery Fund - Cambridge Independent

Amphista Therapeutics earns Series B investment from Dementia Discovery Fund Cambridge Independent

Amphista Therapeutics hires world-leading scientist to boost cancer drug research - insider.co.uk

Amphista Therapeutics hires world-leading scientist to boost cancer drug research insider.co.uk

Nicki Thompson joins Camena Bioscience from Amphista Therapeutics as chair of the board - Cambridge Independent

Nicki Thompson joins Camena Bioscience from Amphista Therapeutics as chair of the board Cambridge Independent

Amphista Therapeutics opens Granta Park research facility - Cambridge Independent

Amphista Therapeutics opens Granta Park research facility Cambridge Independent

University of Dundee biopharmacutical spin-out secures £38 million funding - insider.co.uk

University of Dundee biopharmacutical spin-out secures £38 million funding insider.co.uk

Companies like Amphista Therapeutics Limited

Bicycle Therapeutics logo - Similar company to Amphista Therapeutics Limited

Bicycle Therapeutics

344
Artios logo - Similar company to Amphista Therapeutics Limited

Artios

118
Crescendo Biologics Limited logo - Similar company to Amphista Therapeutics Limited

Crescendo Biologics ...

12
bit.bio logo - Similar company to Amphista Therapeutics Limited

Bit.Bio

164
Quell Therapeutics logo - Similar company to Amphista Therapeutics Limited

Quell Therapeutics

151
TRIMTECH Therapeutics Limited logo - Similar company to Amphista Therapeutics Limited

Trimtech Therapeutic...

15
Apollo Therapeutics logo - Similar company to Amphista Therapeutics Limited

Apollo Therapeutics

61
Alchemab Therapeutics Ltd logo - Similar company to Amphista Therapeutics Limited

Alchemab Therapeutic...

54
Mestag Therapeutics logo - Similar company to Amphista Therapeutics Limited

Mestag Therapeutics

55
Maxion Therapeutics logo - Similar company to Amphista Therapeutics Limited

Maxion Therapeutics

45

Top Amphista Therapeutics Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant